4C Pharma Solutions AS
ASActiveOrg 934186079Smedbergveien 13, 1187 OsloAll other professional, scientific and technical activities n.e.c.· NACE 7499Est. 2024 · 2 years old0 employees
Loading company…
Overview
4C Pharma Solutions AS is a Norwegian AS based in Oslo, operating in the All other professional, scientific and technical activities n.e.c. sector. Incorporated in 2024, the company has 0 employees and reported revenue of NOK 0 in its latest annual filing.
Revenue 2025
0K NOK
EBITDA margin
—
Net profit 2025
-7.9K NOK
0 employees
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20242025
Liquidity ratioCurrent assets ÷ Short-term debt
0.0×
20242025
Return on assets (ROA)Net profit ÷ Total assets × 100
-35.6 %
Very weakAmong the 20% lowest rated companies in the industry
20242025
EBITDA — year on year
NOKKey figures
Annual report 2025| Revenue | 0K NOK | — |
| EBITDA | -7.9K NOK | — |
| Net profit | -7.9K NOK | — |
| Total assets | 22.1K NOK | -26% |
| Equity | 22.1K NOK | -26% |
| Employees | 0 | — |
Company information
Legal name
4C PHARMA SOLUTIONS AS
Org number
934186079
Legal form
Aksjeselskap
Founded
17 September 2024 · 2 years
Share capital
NOK 30,000
Employees
0 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Tjenester til farmasøytiske selskaper som går ut på produktsikkerhet og kvalitet.
(no translation available)
Address
Smedbergveien 13, 1187 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), 4C Pharma Solutions AS reported revenue of NOK 0. The figures on this page draw on 2 annual filings covering 2024 to 2025. The bottom line showed a net loss of NOK 7.9k.
At the end of 2025, equity financed 100% of the balance sheet.
Financials
Revenue
NOKEBITDA
NOKIncome statement
NOK thousands| Item | 2025 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | -0 | -0 |
| EBITDA | -8 | 0 |
| Depreciation & amort. | -0 | -0 |
| EBIT | -8 | 0 |
| Net financials | 0 | 0 |
| Profit before tax | -8 | 0 |
| Tax | -0 | -0 |
| Net profit | -8 | 0 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
NOK thousands| Item | 2025 | 2024 |
|---|---|---|
| Total assets | 22 | 30 |
| Equity | 22 | 30 |
| Long-term debt | 0 | 0 |
| Short-term debt | 0 | 0 |
| Total debt | 0 | 0 |
Financial ratios
5-year trendEBITDA margin
<−999 %
20242025
Equity ratio
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20242025
Return on equity
-35.6 %
Very weakAmong the 20% lowest rated companies in the industry
20242025
Net profit margin
<−999 %
20242025
Asset turnover
0.00×
Very weakAmong the 10% lowest rated companies in the industry
20242025
Debt / equity
0.00×
20242025
Sector performance
12 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Very weak
Among the 20% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Very weak
Among the 20% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Very weak
Among the 20% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Very weak
Among the 20% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Liquidity
Current assets to equityStrong
Among the 40% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Cash conversion ratioAverage
Around the average of companies in the same industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Debt & solvency
Solidity ratioVery strong
Among the 10% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Liabilities to equityVery strong
Among the 10% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Debt ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Income to debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverVery weak
Among the 10% lowest rated companies in the industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Equity to contributed capitalWeak
Among the 30% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
One-year change in debtNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (1)
PT Contact Person | Contact Person | 2024 – 2026 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
YK Board of Directors | Board of Directors | 2024 |
PT Chairman | Chairman | 2024 |
Former (1)
AY Chairman | Chairman | 2024 – 2024 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
4c Pharma Solutions Llc | Company | 100% | 100% | 2025 |
4c Pharma Solutions Llc | Company | 100% | 100% | 2024 |
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
4c Pharma Solutions Llc100%
4C Pharma Solutions AS (this company)Board network connections
Board members of 4C Pharma Solutions AS also hold positions in 15 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pavel Teplykh | Contact Person | 9 companiesMany roles |
| Anna Yevseyeva | Chairman | 6 companiesMany roles |
Frequently asked questions
What is the Org number of 4C Pharma Solutions AS?
4C Pharma Solutions AS is registered with Brønnøysundsregistrene under Org 934186079.
Who is the chairman of 4C Pharma Solutions AS?
Pavel Teplykh chairs the board of 4C Pharma Solutions AS.
Where is 4C Pharma Solutions AS headquartered?
4C Pharma Solutions AS's registered address is Smedbergveien 13.